Aza-ꢀ3-cyclotetrapeptides
important roles as recognition and binding sites in numerous
biological events.5 ꢀ-Turns are also implied in the receptor
affinity of Somatostatin,6 Bradykinin,7 and other biologically
important peptides.8,9 Natural CTPs also display interesting
biological effects.10 In particular, Apicidin shows antiprotozoal
activities with possible development as antimalarial agents.11
Yet, all these attractive features are counterbalanced by the fact
that the CTP scaffold, with four planar amide groups constrained
in a 12-membered ring, remains hardly accessible syntheti-
cally.12 Several groups, both academic and pharmaceutical, have
developed new synthetic strategies to obtain easily accessible
natural CTP analogues, with high conformational homogeneity.
The incorporation of a single ꢀ3-amino acid, which induces a
pseudo γ-turn, gives efficient synthesis of rigid 13-membered
ring CTP mimetics,13 also used to develop RGD mimetics.14
The introduction of a reduced peptide bond proved to be a
valuable approach toward the synthesis of Apicidin analogues.15
Cyclic ꢀ-tetrapeptoids also appear as a novel promising scaf-
fold.16
Arnaud Salau¨n,† Cle´mence Mocquet,† Romain Perochon,†
Aure´lien Lecorgne,† Barbara Le Grel,† Michel Potel,‡ and
Philippe Le Grel*,†
ICMV and CSM, UMR CNRS 6226, UniVersite´ de Rennes I,
263 aVenue du Ge´ne´ral Leclerc, 35042 Rennes, Cedex, France
philippe.legrel@uniV-rennes1.fr
ReceiVed June 26, 2008
Aza-ꢀ3-peptides,17 built up with NR-substituted hydrazinoace-
tic acids18 (aza-ꢀ3-amino acids) (Figure 1, top), are pseudopep-
tides which differ mainly from regular peptides by the replace-
ment of amide bonds by hydrazide bonds and the location of
the chirality on the NR nitrogen centers (Figure 1, middle). These
pseudopeptidic foldamers are characterized by an intramolecular
H-bond network (Figure 1, bottom) based on a repeated
bifurcated C8 pseudocycle (hydrazinoturn) and a phenomenon
of chiral scanning along the backbone resulting from nitrogen
The cyclization of aza-ꢀ3-tetrapeptides gives access to new
CTP (cyclotetrapeptide) analogues. These stereocontrolled
templates are assembled without any asymmetric synthesis.
X-ray crystallographic structure and NMR analysis show
that the macrocyclic scaffold is characterized by a fully
cooperative intramolecular H-bond network, in sharp
contrast with the nanotubular assemblies observed for ꢀ3-
cyclotetrapeptides. This folding property reduces consider-
ably the polarity of aza-ꢀ3-tetrapeptides and should be useful
in addressing intracellular targets.
(5) (a) Lewis, P. N.; Nomany, F. A.; Sheraga, H. A. Proc. Natl. Acad. Sci.
U.S.A. 1971, 68, 2293. (b) Wilmot, C. M.; Thornton, J. M. J. Mol. Biol. 1988,
203, 221. (c) Suat, K. K.; Seetharama, D. S. J. Curr. Pharm. Des. 2003, 9,
1209.
(6) Hirschmann, R.; Nicolaou, K. C.; Pietranico, S.; Salvino, J.; Leahy, E. M.;
Sprengler, P. A.; Furst, G.; Smith, A. B.; Strader, C. D.; Casieri, M. A.;
Candelore, M. R.; Donaldson, G.; Maechler, L. J. Am. Chem. Soc. 1992, 114,
9217.
Cyclization is a common tool to introduce steric and angular
constraints in small peptidic segments, and to probe the
conformational requirements for biological activity.1 Cyclotet-
rapeptides (CTPs) seem attractive for drug design, due to a
molecular weight ranging in the drug-like gap, to an intrinsic
resistance to exopeptidases but also to endopeptidases which
are mostly active against ꢀ-strand conformation,2 and to the
potential side chain diversity that can be introduced by using
both proteogenic and nonproteogenic amino acids.3 Their cyclic
nature makes them more rigid than the linear precursors, what
is an entropic advantage upon binding, although they can show
residual conformational heterogeneity.4 CTPs represent mini-
malist ꢀ-turns mimetics, the most common reverse turn,
comprising four amino acid residues making almost a complete
180° turn in the direction of the peptide chain. ꢀ-Turns, generally
located on the solvent-exposed surface of proteins, play
(7) Miskolzie, M.; Yamamoto, H.; York, E. J.; Stewart, J. M.; Kotovych, G.
J. Biomol. Struct. Dyn. 2000, 17, 947.
(8) Zhang, J.; Xiong, C.; Ying, J.; Wang, W.; Hruby, V. J. Org. Lett. 2003,
5, 3115.
(9) Freidinger, R. M.; Veber, D. F.; Perlow, D. S.; Brooks, J. R.; Saperstein,
S. Science 1980, 210, 656.
(10) (a) Liech, J. M.; Sweeley, C. C.; Staffeld, G. D.; Anderson, M. S.;
Webber, D. J.; Scheffer, R. P. Tetrahedron 1982, 38, 45. (b) Taunton, J.; Collins,
J. L.; Schreiber, S. L. J. Am. Chem. Soc. 1996, 118, 10412. (c) Kawai, M.;
Pottorf, R. S.; Rich, D. H. J. Med. Chem. 1986, 29, 2409. (d) Templeton, G. E.
Microb. Toxins 1972, 8, 160. (e) Pringle, R. B. Plant Physiol. 1970, 46, 45.
(11) Darkin-Rattray, S. J.; Gurnett, A. M.; Myers, R. W.; Dulski, P. M.;
Crumley, T. M.; Alloco, J. J.; Cannova, C.; Meinke, P. T.; Colleti, S. L.;
Bednarek, M. A.; Singh, S. B.; Goetz, M. A.; Dombrowski, A. W.; Polishook,
J. D.; Schmatz, D. M. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 13143.
(12) (a) Cavelier-Fronton, F.; Pe`pe, G.; Verducci, J.; Siri, D.; Jacquier, R.
J. Am. Chem. Soc. 1992, 114, 8885. (b) Pastuszak, J.; Gardner, J. H.; Singh, J.;
Rich, D. H. J. Org. Chem. 1982, 47, 2982.
(13) Glenn, M. P.; Kelso, M. J.; Tyndall, J. D.; Fairlie, D. P. J. Am. Chem.
Soc. 2003, 125, 640.
(14) Schumann, F.; Mu¨ller, A.; Koksch, M.; Mu¨ller, G.; Sewald, N. J. Am.
Chem. Soc. 2000, 122, 12009.
(15) Murray, P. J.; Kranz, M.; Ladlow, M.; Taylor, S.; Berst, F.; Holmes,
A. B.; Keavey, K. N.; Jaxa-Chamiec, A.; Seale, P. W.; Stead, P.; Upton, R. J.;
Croft, S. L.; Clegg, W.; Elsegood, M. R. Bioorg. Med. Chem. Lett. 2001, 11,
773.
(16) Roy, O.; Faure, S.; Thery, V.; Didierjean, C.; Taillefumier, C. Org. Lett.
2008, 10, 921.
(17) Cheguillaume, A.; Salau¨n, A.; Sinbandhit, S.; Potel, M.; Gall, P.; Baudy-
Floc’h, M.; Le Grel, P. J. Org. Chem. 2001, 66, 4923.
(18) Cheguillaume, A.; Doubli-Bounoua, I.; Baudy-Floc’h, M.; Le Grel, P.
Synlett 2000, 3, 331.
† ICMV.
‡ CSM.
(1) Rizo, J.; Gierash, L. M. Annu. ReV. Biochem. 1992, 61, 387–418.
(2) Tyndall, J. D. A.; Nall, T.; Fairlie, D. P. Chem. ReV. 2005, 105, 973.
(3) Che, Y.; Marshall, G. R. J. Med. Chem. 2006, 49, 111.
(4) (a) Kessler, H. Angew. Chem., Int. Ed. 1982, 21, 512. (b) Cuniasse, P.;
Raynal, I.; Yiotakis, A.; Dive, V. J. Am. Chem. Soc. 1997, 119, 5239. (c) Loiseau,
N.; Gomis, J. M.; Santolini, J.; Delaforge, M.; Andre´, F. Biopolymers 2003, 69,
363.
10.1021/jo8013963 CCC: $40.75
Published on Web 10/08/2008
2008 American Chemical Society
J. Org. Chem. 2008, 73, 8579–8582 8579